Acura Pharmaceuticals Inc. has announced an amendment to their existing loan agreement with Abuse Deterrent Pharma, LLC, as detailed in a recent Form 8-K filing. The amended loan schedule, dated November 10, 2022, outlines a series of additional loans, with the aggregate principal amount now reaching $8,694,279. This update includes new loans numbered 27 through 43, spanning from January 2025 to September 2025, each with varying amounts. The amendment reflects Acura Pharmaceuticals' continued efforts to secure necessary funding for its operations. The agreement was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals, on September 3, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-087312), on September 04, 2025, and is solely responsible for the information contained therein.